Market Cap
$2.3B
HRMY
Harmony Biosciences Holdings, Inc.
$39.57 ▲ +0.79%
Prev close $39.26Market cap$2.3B
ConsensusBuy
12-mo target$47.64 (+20.4%)
▲ Bullish
Analyst conviction 7/10
High Impact Filing (7/10)24 New Institutional Positions26 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on HRMY right now — valuation, ownership and activity at a glance.
Cap Size
Mid Cap
Analyst Consensus
Strong Buy (71%)
Inst. Holders
50 funds
Inst. Value
$1.5B
Inst. Activity
24 buys / 26 sells
Insider Activity
$0.00 buy / $3.1M sell
Insider Net $
-$3.1M
Social Sentiment
50° Neutral
SEC Reports
12
Price chart 30d -7.7%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Apr 1, 2027 fda_pdufa
PDUFA: HRMY — Pitolisant GR in narcolepsy — 2027-04-01
FDA target action date 2027-04-01 for HRMY (Harmony Biosciences Holdings, Inc.). Drug: Pitolisant GR
Sep 18, 2026 Insider
Budur Kumar acquired via exercise 10,406 shares
CHIEF MEDICAL OFFICER @ $30.69 ($319.4K)
Sep 18, 2026 Insider
Budur Kumar acquired via exercise 25,446 shares
CHIEF MEDICAL OFFICER @ $30.27 ($770.3K)
Sep 18, 2026 Insider
Aug 4, 2026 SEC Budur Kumar sold 35,852 shares
CHIEF MEDICAL OFFICER @ $43.05 ($1.5M)
Harmony Biosciences reported record Q2 2026 WAKIX net revenue of $261.3M (+30% YoY), with GAAP diluted EPS of $1.28 beat
8-K — Impact 7/10
Harmony Biosciences reported Q2 2026 WAKIX net revenue of $261.3M, up 30% YoY and above $253.3M consensus, with diluted
PRESS-RELEASE — Impact 6/10
Harmony Biosciences pre-announced record Q2 2026 WAKIX net product revenue of ~$261M (+30% YoY), reaffirmed full-year gu
8-K — Impact 7/10
Jun 30, 2026 Inst.
Valor Management LLC — DOUBLED
818,013 shares ($29.8M)
Analyst ratings buy % -13.4%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
71% rate it Buy or better · 17 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Aug 26, 2026 | Wolfe Research | INITIATE | Outperform | 52% |
| Aug 5, 2026 | Truist Securities | MAINTAIN | Hold | 55% |
| Aug 4, 2026 | Needham | MAINTAIN | Buy | 50% |
| Jul 31, 2026 | Mizuho | MAINTAIN | Outperform | 52% |
| Jul 16, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Jun 30, 2026 | Deutsche Bank | MAINTAIN | Hold | 58% |
| May 8, 2026 | Truist Securities | MAINTAIN | Hold | 55% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 4 | 8 | 4 | 1 | 0 | 71% | |
| Aug 1, 2026 | 3 | 8 | 4 | 1 | 0 | 69% | |
| Jul 1, 2026 | 3 | 8 | 5 | 1 | 0 | 65% | |
| Jun 1, 2026 | 3 | 8 | 5 | 1 | 0 | 65% | |
| May 1, 2026 | 3 | 8 | 5 | 1 | 0 | 65% | |
| Apr 1, 2026 | 3 | 8 | 5 | 1 | 0 | 65% | |
| Mar 1, 2026 | 3 | 8 | 5 | 1 | 0 | 65% | |
| Feb 1, 2026 | 3 | 11 | 2 | 1 | 0 | 82% |
Price targets
Where 11 covering analysts think HRMY trades over the next 12 months.
$47.64 +20.4% upside Strong Buy
Current$39.57 Low$30.00 Median$50.00 High$70.00 11 analysts
$30.00$70.00
Analyst rating Buy· 2.0/5 as of Oct 2, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
50°
Neutral
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
12 SEC filing reports analyzed · 3 bullish, 2 bearish, 2 mixed, 5 neutral · avg impact 4.8/10.
BULLISH8-K7/10
Harmony Biosciences reported record Q2 2026 WAKIX net revenue of $261.3M (+30% YoY), with GAAP dilut
Aug 4, 2026
BULLISHPRESS-RELEASE6/10
Harmony Biosciences reported Q2 2026 WAKIX net revenue of $261.3M, up 30% YoY and above $253.3M cons
Aug 4, 2026
BULLISH8-K7/10
Harmony Biosciences pre-announced record Q2 2026 WAKIX net product revenue of ~$261M (+30% YoY), rea
Jul 16, 2026
BEARISH1445/10
Former officer Sandip Kapadia filed a Form 144 notice to sell 50,000 shares of Harmony Biosciences,
Jul 3, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Apr 1, 2027
fda_pdufa
PDUFA: HRMY — Pitolisant GR in narcolepsy — 2027-04-01
FDA target action date 2027-04-01 for HRMY (Harmony Biosciences Holdings, Inc.). Drug: Pitolisant GR. Indication: narcolepsy. Target PDUFA date for pi
Mar 31, 2027
fda_pdufa
PDUFA: HRMY — Pitolisant GR in narcolepsy (Adults) — 2027-03-31
FDA target action date 2027-03-31 for HRMY (Harmony Biosciences Holdings, Inc.). Drug: Pitolisant GR. Indication: narcolepsy (Adults). Anticipated PDU
Oct 1, 2026
fda
Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days
PLYMOUTH MEETING, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present a post
Sep 25, 2026
Clinical Trial
A Phase 3 Study to Assess the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia
Phase Phase 3 — COMPLETED
Sep 18, 2026
short_volume
Short Volume: HRMY — 70.5% short (0.4M / 0.6M)
Short: 448,692 | Exempt: 0 | TRF Vol: 636,377 | Short Ratio: 70.5% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $1.47 | $1.41–$1.53 | 35.9% | +0.0% | 3↑ 0↓ | $0.3B | 2 |
| Next Q | $1.53 | $1.45–$1.60 | 168.0% | +0.0% | 0↑ 3↓ | $0.3B | 2 |
| Current FY | $5.22 | $5.13–$5.31 | 45.0% | +0.0% | 2↑ 1↓ | $1.0B | 2 |
| Next FY | $7.00 | $6.98–$7.03 | 34.1% | +4.8% | 1↑ 2↓ | $1.2B | 2 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $1.468 | — |
| 7d ago | $1.468 | — |
| 30d ago | $1.468 | — |
| 60d ago | $1.224 | +0.243 |
| 90d ago | $1.224 | +0.243 |
Institutional ownership
Which big funds own HRMY (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $1.5B total value (40,035,680 shares) as of 2026-Q2. Top holders: BlackRock,, FMR, VANGUARD. Net selling activity: 26 institutions trimmed/exited vs 24 added.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 7,101,965 | $258.6M | 17.8% | — |
| FMR LLC | 3,574,115 | $130.1M | 8.9% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2,880,489 | $104.9M | 7.2% | — |
| AMERICAN CENTURY COMPANIES INC | 2,539,512 | $92.5M | 6.4% | — |
| DIMENSIONAL FUND ADVISORS LP | 2,393,588 | $87.1M | 6.0% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 2,105,053 | $76.6M | 5.3% | — |
| STATE STREET CORP | 1,859,322 | $67.7M | 4.7% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 1,442,649 | $52.5M | 3.6% | — |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 1,312,550 | $47.8M | 3.3% | — |
| RENAISSANCE TECHNOLOGIES LLC | 1,195,371 | $43.5M | 3.0% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| Valor Management LLC | DOUBLED | 117,130 | 818,013 | +598.4% | $29.8M |
| MORGAN STANLEY | TRIM | 1,031,018 | 733,684 | -28.8% | $26.7M |
| UBS Group AG | ADD | 447,991 | 602,990 | +34.6% | $22.0M |
| JPMORGAN CHASE & CO | TRIM | 823,513 | 514,085 | -37.6% | $18.2M |
| GOLDMAN SACHS GROUP INC | TRIM | 1,239,207 | 403,532 | -67.4% | $14.7M |
| MILLENNIUM MANAGEMENT LLC | TRIM | 954,359 | 319,812 | -66.5% | $11.6M |
| CITADEL ADVISORS LLC | TRIM | 585,623 | 255,810 | -56.3% | $9.3M |
| Jump Financial, LLC | DOUBLED | 79,508 | 214,605 | +169.9% | $7.8M |
| FIRST TRUST ADVISORS LP | ADD | 104,549 | 190,574 | +82.3% | $6.9M |
| Trexquant Investment LP | TRIM | 594,850 | 174,700 | -70.6% | $6.4M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
11 insiders, 28 transactions. Net -$3.1M — $0.00 bought, $3.1M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 18, 2026 | Budur Kumar | CHIEF MEDICAL OFFICER | EXERCISE | 10,406 | $30.69 | $319.4K |
| Sep 18, 2026 | Budur Kumar | CHIEF MEDICAL OFFICER | EXERCISE | 25,446 | $30.27 | $770.3K |
| Sep 18, 2026 | Budur Kumar | CHIEF MEDICAL OFFICER | SELL | 35,852 | $43.05 | $1.5M |
| Sep 17, 2026 | Budur Kumar | CHIEF MEDICAL OFFICER | EXERCISE | 400 | $30.27 | $12.1K |
| Sep 17, 2026 | Budur Kumar | CHIEF MEDICAL OFFICER | EXERCISE | 400 | $30.69 | $12.3K |
| Sep 17, 2026 | Budur Kumar | CHIEF MEDICAL OFFICER | SELL | 800 | $43.00 | $34.4K |
| Sep 16, 2026 | Budur Kumar | CHIEF MEDICAL OFFICER | EXERCISE | 900 | $30.69 | $27.6K |
| Sep 16, 2026 | Budur Kumar | CHIEF MEDICAL OFFICER | EXERCISE | 900 | $30.27 | $27.2K |
| Sep 16, 2026 | Budur Kumar | CHIEF MEDICAL OFFICER | SELL | 1,800 | $43.01 | $77.4K |
| Sep 8, 2026 | Budur Kumar | CHIEF MEDICAL OFFICER | SELL | 4,500 | $42.25 | $190.1K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for HRMY.
Shares short
4,628,716
Settlement Sep 15, 2026
Change vs prior
-10.4%
Semi-monthly cycle
Days to cover
4.3
At avg daily volume
Of shares outstanding
≈8.0%
Estimate — not % of float
All HRMY filing & press-release reports (12)
- 8-K reportAug 4, 2026
- PRESS-RELEASE reportAug 4, 2026
- 8-K reportJul 16, 2026
- 144 reportJul 3, 2026
- 144 reportJun 25, 2026
- 144 reportJun 9, 2026
- 144 reportJun 5, 2026
- 3 reportMay 19, 2026
- 8-K reportMay 7, 2026
- 8-K reportApr 14, 2026
- DEFA14A reportApr 3, 2026
- 8-K reportApr 2, 2026